Google
OVID — OVID THERAPEUTICS INC (Healthcare >> Biotechnology)
OVID FAQ
What is OVID's P/E ratio?
OVID THERAPEUTICS INC (OVID) currently trades at a P/E ratio of 45.58.
What is OVID's ROE?
OVID THERAPEUTICS INC reports a Return on Equity (ROE) of -12.19%.
What is OVID's dividend yield?
OVID THERAPEUTICS INC offers a dividend yield of 0.00%.
What is OVID's Deepscope Quality Score?
Deepscope rates OVID's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OVID?
Deepscope's AI Timing Score for OVID is 57 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OVID belong to?
OVID THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.42
Price
0.06
(2.54%)
Day Change
|
|
|---|
OVID, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.42 |
| PBV / Sector |
2.22 / 4.71
|
| Earning Per Share | -0.13 |
| PE / Sector |
45.58 / 17.58
|
| PEG or PE/Growth / Sector |
-1.61 / 0.53
|
| Average 1M Daily Value |
4.09 M
GREAT
|
| Average 1W Daily Value |
3.76 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:39 |
| Symbol | OVID |
| Name | OVID THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 186.64 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 440.47 / 8,889.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Hudson Commons, New York, NY, United States, 10001
Phone: 646 661 7661
Website: https://www.ovidrx.com
Sector: Healthcare >> Biotechnology
Description: Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
